Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Surg Laparosc Endosc Percutan Tech. 2020 Apr;30(2):187-191. doi: 10.1097/SLE.0000000000000755.
The purpose of the current study was to analyze the safety and efficacy of endoscopic resection for gastric subepithelial tumors (SETs) using long-term patient outcome data.
A retrospective analysis of 73 consecutive patients with gastric SETs was performed from June 2014 to December 2016. The treatment methods included submucosal dissection, submucosal excavation or endoscopic full-thickness resection (EFTR). In addition to epidemiological data (sex and age), tumor size, surgical parameters, length of stay, complications, costs, and endoscopic, clinicopathologic, and follow-up data were analyzed to compare treatments.
The complete resection rate was 97.3% (71/73). Three patients experienced complications (4.1%), including 2 with delayed perforation and 1 with perioperative infection. The median postoperative feeding time was 3 days, and the median postoperative hospital stay was 5 days. The median follow-up period was 19 months, with no patient death or tumor recurrence. Among the 38 patients with gastrointestinal stromal tumors, the complete resection rate was 97.4% (37/38). The complete resection and complication rates between the endoscopic submucosal excavation (ESE) group and the EFTR group were not statistically significant. There was no recurrence or metastasis detected among either group; however, the ESE group had earlier postoperative feeding, a shorter postoperative hospital stay, and less hospitalization expenses.
Endoscopic resection for gastric SETs (<3 cm) is safe and feasible concerning medium-term and long-term effects. Compared with the EFTR group, the ESE group had earlier postoperative feeding, a shorter postoperative hospital stay, and less hospitalization expenses. Even so, gastric SETs with malignant potential are at risk of recurrence. Larger prospective multicenter studies are warranted.
本研究旨在通过长期患者预后数据,分析内镜下切除胃黏膜下肿瘤(SETs)的安全性和有效性。
回顾性分析 2014 年 6 月至 2016 年 12 月期间 73 例胃 SETs 患者的临床资料。治疗方法包括黏膜下剥离术、黏膜下挖除术或内镜全层切除术(EFTR)。除了流行病学数据(性别和年龄)、肿瘤大小、手术参数、住院时间、并发症、费用以及内镜、临床病理和随访数据外,还分析了治疗方法。
完全切除率为 97.3%(71/73)。3 例患者发生并发症(4.1%),包括 2 例延迟穿孔和 1 例围手术期感染。术后中位进食时间为 3 天,中位住院时间为 5 天。中位随访时间为 19 个月,无患者死亡或肿瘤复发。在 38 例胃肠道间质瘤患者中,完全切除率为 97.4%(37/38)。内镜黏膜下挖除术(ESE)组和 EFTR 组的完全切除率和并发症发生率无统计学差异。两组均未发现复发或转移;然而,ESE 组术后进食更早,术后住院时间更短,住院费用更少。
内镜切除胃 SETs(<3cm)在中、长期疗效方面是安全可行的。与 EFTR 组相比,ESE 组术后进食更早,术后住院时间更短,住院费用更少。尽管如此,具有恶性潜能的胃 SETs 仍有复发的风险。需要更大规模的前瞻性多中心研究。